SCHEMBL25178797

SCHEMBL25178797

O=C(O)C(O)(c1cccc(Br)c1)C1CCC1

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.64
NFE2L2 Q16236 1/20 0.64
GRK2 P25098 1/20 0.42
CASP6 P55212 1/20 0.42
CASP8 Q14790 1/20 0.42
CTDSP1 Q9GZU7 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
CHRM3 P20309 10/20 0.41
CHRM2 P08172 5/20 0.41
CHRM1 P11229 4/20 0.41
ALDH1A1 P00352 2/20 0.39
CHRM4 P08173 1/20 0.37
CHRM5 P08912 1/20 0.37
HRH1 P35367 1/20 0.37
HTR2B P41595 1/20 0.37
KCNH2 Q12809 1/20 0.37
CYP1A2 P05177 1/20 0.37
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30891981 1.00 KEAP1 (0.64) KEAP1NFE2L2GRK2CASP6CASP8
SCHEMBL25183653 0.84 ALDH1A1 (0.44) KEAP1NFE2L2CHRM3CHRM2CHRM1
SCHEMBL6590164 0.82 KEAP1 (0.93) KEAP1NFE2L2CHRM3CHRM2CHRM1
SCHEMBL3913217 0.82 KEAP1 (0.93) KEAP1NFE2L2CHRM3CHRM2CHRM1
SCHEMBL2763565 0.82 KEAP1 (0.93) KEAP1NFE2L2CHRM3CHRM2CHRM1
SCHEMBL22832489 0.81 KEAP1 (0.43) KEAP1NFE2L2GRK2CASP6CASP8
SCHEMBL6587160 0.79 KEAP1 (0.69) KEAP1NFE2L2CHRM3CHRM2CHRM1
SCHEMBL2062949 0.79 KEAP1 (1.00) KEAP1NFE2L2CHRM3CHRM2CHRM1
SCHEMBL415801 0.79 KEAP1 (1.00) KEAP1NFE2L2CHRM3CHRM2CHRM1
SCHEMBL418664 0.79 KEAP1 (1.00) KEAP1NFE2L2CHRM3CHRM2CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12187709-B2 Lactams as CBL-B inhibitors selective over C-CBL GENENTECH, INC. (US) 2025-01-07 US disclosed
EP-4426691-A1 LACTAMS AS CBL-B INHIBITORS SELECTIVE OVER C-CBL Genentech, Inc. (US) 2024-09-11 EP disclosed
CN-118201921-A Lactams as CBL-B inhibitors selective for C-CBL 基因泰克公司 2024-06-14 CN disclosed
US-20230212153-A1 LACTAMS AS CBL-B INHIBITORS SELECTIVE OVER C-CBL GENENTECH, INC. (US) 2023-07-06 US disclosed
WO-2023081853-A1 LACTAMS AS CBL-B INHIBITORS SELECTIVE OVER C-CBL GENENTECH, INC. (US) 2023-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212153-A1 LACTAMS AS CBL-B INHIBITORS SELECTIVE OVER C-CBL CBL, CBLB, CBLC KEAP1 363/4885NFE2L2 2321/4885GRK2 3035/4885
US-12187709-B2 Lactams as CBL-B inhibitors selective over C-CBL CBL, CBLB, CBLC KEAP1 363/4885NFE2L2 2321/4885GRK2 3035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.